Study Summary
The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test it in a new group of participants to see if it is effective in treating their relapsed/refractory AML.
Want to learn more about this trial?
Request More InfoInterventions
ADCLEC.syn1 CAR T cellsBIOLOGICAL
There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.
Conditioning chemotherapyDRUG
Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | United States |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | United States |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | United States |
| Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) | Commack | New York | United States |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | United States |